Neutrophil secondary necrosis is induced by LL-37 derived from cathelicidin

被引:53
|
作者
Zhang, Zhifang [1 ]
Cherryholmes, Gregory [1 ]
Shively, John E. [1 ]
机构
[1] City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA
基金
美国国家卫生研究院;
关键词
apoptosis; CXCR2; IL-8; IL-1Ra;
D O I
10.1189/jlb.0208086
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Neutrophils represent the most common granulocyte subtype present in blood. The short half-life of circulating neutrophils is regulated by spontaneous apoptosis, and tissue infiltrating neutrophils die by apoptosis and secondary necrosis. The mechanism of neutrophil apoptosis has been the subject of many studies; however, the mechanism of neutrophil secondary necrosis is less clear. Human cathelicidin cationic peptide 18, proteolytically processed to its active form, LL-37, is secreted by neutrophils and epithelial cells and shown to have effects in addition to bacterial lysis. We demonstrate here that LL-37 affects neutrophil lifespan by the pathway of secondary necrosis, rapidly converting annexin V-positive (AV(+)), propidium iodide-negative (PI-; apoptotic) cells into PI+ (necrotic) cells with the release of IL-8, IL-1R antagonist, ATP, and intact granules. The effects of LL-37 on apoptotic neutrophils are neither energy-dependent nor affected by pretreatment with G-CSF, GM-CSF, TNF-alpha, and LPS and are partially inhibited by human serum. Moreover, LL-37 decreases CXCR2 expression of AV(-)PI(-) (live)neutrophils, suggesting an effect on the neutrophil response to its chemotactic factors, including IL-8. Thus, the lifespan and inflammatory functions of neutrophils are directly affected by LL-37.
引用
收藏
页码:780 / 788
页数:9
相关论文
共 50 条
  • [41] Pulmonary defense and the human cathelicidin hCAP-18/LL-37
    Fahy, RJ
    Wewers, MA
    IMMUNOLOGIC RESEARCH, 2005, 31 (02) : 75 - 89
  • [42] Cathelicidin LL-37: a defense molecule with a potential role in psoriasis pathogenesis
    Dombrowski, Yvonne
    Schauber, Juergen
    EXPERIMENTAL DERMATOLOGY, 2012, 21 (05) : 327 - 330
  • [43] The roles of cathelicidin LL-37 in immune defences and novel clinical applications
    Nijnik, Anastasia
    Hancock, Robert E. W.
    CURRENT OPINION IN HEMATOLOGY, 2009, 16 (01) : 41 - 47
  • [44] LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity
    Adam Fabisiak
    Natalia Murawska
    Jakub Fichna
    Pharmacological Reports, 2016, 68 : 802 - 808
  • [45] Cathelicidin peptide LL-37: A multifunctional peptide involved in heart disease
    Miao, Shuo
    Liu, Houde
    Yang, Qingyu
    Zhang, Yaping
    Chen, Tao
    Chen, Shuai
    Mao, Xin
    Zhang, Qingsong
    PHARMACOLOGICAL RESEARCH, 2024, 210
  • [46] The Human Cathelicidin LL-37, a Defensive Peptide Against Rotavirus Infection
    Zohreh Hosseini
    Mohammad Bagher Habibi Najafi
    Masoud Yavarmanesh
    Angila Ataei-Pirkooh
    International Journal of Peptide Research and Therapeutics, 2020, 26 : 911 - 919
  • [47] In silico assessment of missense point mutations on human cathelicidin LL-37
    Porto, William F.
    Alencar, Sergio A.
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2023, 118
  • [48] Expression of B-defensins, cathelicidin (LL-37) in skin tumors
    Whang, Kyu Uang
    Mo, Gang
    Lee, Jong Suk
    Lip, Young
    Lee, Jung Eun
    Hoon, Jung
    Park, Yoon Ji
    Il, Seung
    Kim, Ji Hoon
    Ki, Hong
    JOURNAL OF DERMATOLOGY, 2012, 39 : 34 - 34
  • [49] Serum levels of peptide cathelicidin LL-37 in elderly patients with depression
    Kozlowska, Elzbieta
    Wysokinski, Adam
    Brzezinska-Blaszczyk, Ewa
    PSYCHIATRY RESEARCH, 2017, 255 : 156 - 160
  • [50] Circulating cathelicidin LL-37 in adult patients with pulmonary infectious diseases
    Majewski, Karol
    Zelechowska, Paulina
    Brzezinska-Blaszczyk, Ewa
    CLINICAL AND INVESTIGATIVE MEDICINE, 2017, 40 (01): : E34 - E39